Australian biopharmaceutical company Immuron (ASX:IMC) has submitted a response letter to the US FDA in response to its clinical hold on trials of the new oral therapeutic targeting campylobacter. …
Latest Video
New Stories
-
The 'Week in Review' - 27 January
January 27, 2023 - - Podcast -
Forget about experts and terms of reference until we get a transparent process
January 27, 2023 - - Latest News -
Australia Day recognition for senior officials and pharmacy leaders
January 27, 2023 - - Latest News -
Is this a change of heart from the former health department secretary?
January 27, 2023 - - Latest News -
New chair for Australian genomics industry organisation
January 26, 2023 - - Australian Biotech -
MEDLAB receives Import Certificate from UK Home Office for NanaBis
January 26, 2023 - - Australian Biotech -
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 - - Australian Biotech